October 6, 2015 News by Patricia Silva, PhD Icometrix Collaborates with Novartis on MSmetrix Software Application, New Data at Upcoming ECTRIMS 2015 Conference Icometrix, a leader in magnetic resonance imaging (MRI) biomarkers for multiple sclerosis (MS), has recently announced a collaboration agreement with Novartis Pharma AGĀ regardingĀ MSmetrix ā a measurement tool especially designed to assess brain volume and atrophy, as well as existing, new or enlarging brain lesions in MS patients. Monitoring…
July 22, 2015 News by admin New Study Evaluates The Role of MRI in Monitoring MS Progression Multiple sclerosis (MS) is a devastating, progressive disease of the nervous system. It is caused by loss of myelin, aĀ fatty substance that wraps around nerve cells and allows them to conduct impulses and communicate. When myelin is lost, areas of damage called “lesions” result, which appear in the brain and…
May 21, 2015 News by admin 11-Year Follow-up of Bayer’s BENEFIT Interferon-beta1b Treatment Reveals Positive Results For MS Patients Results from the BENEFIT11 trial indicate thatĀ early treatment with IFNB-1b leads to improvements inĀ cognition and fatigue in the long-term, as well as sustained employment and favorable magnetic resonance imaging (MRI) outcomes, measured at the 11-year mark. Supported byĀ Bayer HealthCare Pharmaceuticals, the study, titled “Long-term Impact of Early MS Treatment with…
February 17, 2015 News by admin Multiple Sclerosis: How Can MRI Measurements be Improved in Trials? A study from German researchers might help to determine how multiple sclerosis is assessed in treatment trials. Published February 6 in the journal PLoS ONE, the study is titled “Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts –…
January 6, 2015 News by Patricia Silva, PhD RRMS Study Using MRI Reveals Benefits of Experimental Therapy in Achieving No Evidence of Disease Activity Results from aĀ Phase 3 clinical trial entitled “AVANCE” revealed promising clinical outcomes in patients with relapsing-remitting multiple sclerosis treated forĀ one year with peg interferon beta-1a. The analysis wasĀ published in the journal BMC Neurology, in a study entitled āEffect of peg interferon beta-1a on MRI measures and…
November 4, 2014 News by Patricia Inacio, PhD MRIs are Revealing Multiple Sclerosis in Patients, Even Before Symptoms Begin A study entitled āLongitudinal Follow-up of a Cohort of Patients with Incidental Abnormal Magnetic Resonance Imaging Findings at Presentation and Their Risk of Developing Multiple Sclerosisā published in the International Journal of MS Care reports that asymptomatic patients accompanied by Magnetic Resonance Images suggestive of…
September 10, 2014 News by Charles Moore New MRI Study Shows Strong Correlation Of Gray Matter Myelin Loss To MS Disability Loss of myelin, the fatty protective sheath around nerve fibers, is a characteristic of multiple sclerosis (MS). A new magnetic resonance imaging (MRI) study by a team of researchers has determined that people with MS lose myelin in the gray matter of their brains, and that the amount of loss…
June 16, 2014 News by Patricia Silva, PhD Researcher Recommends Brain Imaging To Treat MS-Related Depression Magnetic resonance imaging (MRI) can predict responses to depression treatment in patients with multiple sclerosis (MS), according to Anthony Feinstein, Professor at the Department of Psychiatry of the Sunnybrook Health Sciences Centre & the University of Toronto. In the presentation āDepression in MS: Is brain imaging helpful?ā at this…